ClinicalTrials.gg
Status unknownNCT06346951IFSUpdated Apr 4, 2024

Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS)

An observational study in Invasive Fungal Infections, sponsored by Sichuan Provincial People's Hospital. Status unknown. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Sichuan Provincial People's Hospital · Observational

The sponsor has not verified this record recently (last verified Apr 2024), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Sex
All
01

Study summary

The goal of this survey is to learn about the current status of the diagnosis and treatment of invasive fungal infections among intensive care physicians in Sichuan Province (IFS). Its primary focus lies on answering the following questions: ①awareness and proficiency in diagnosis and treatment; ②the use of antifungal medications; ③the application of microbiological identification and diagnostic methods. We aim to analyze the problems and deficiencies that existed among intensive care physicians in order to provide a basis for the development of targeted training and intervention measures.

02

Conditions studied

  • Invasive Fungal Infections
03

In context

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

This study's planned enrollment of 300 is above the median of 125 across 66 observational studies indexed under Invasive Fungal Infections.

Browse Invasive Fungal Infections studies →

Lead sponsor

Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Intensive care physicians in medical institutions at all levels in Sichuan Province. Anticipated total of 20 centers will participate in the study, with a total of 300 physicians to be included in the survey.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Intensive care physicians in medical institutions at all levels in Sichuan Province

Exclusion criteria

Exclusion Criteria:

  • Exclude non-Sichuan physicians.
  • Excluding physicians who are not engaged in intensive care unit.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The survey on the hospital's diagnostic and treatment standards and infrastructure for invasive fungal infections

    ①To investigate the basic knowledge and skill mastery of invasive fungi diagnosis and treatment by intensive care physicians in Sichuan province, including information on pathogenesis, clinical manifestations, diagnosis, and treatment. ② To investigate the concerns and selection tendency of intensive care physicians in Sichuan province in choosing antifungal drugs in practice, including information on treatment types, drug choice, dosage, and treatment course.

    Time frame: From enrollment to the end of survey at 16 weeks

  2. The survey on the awareness of an invasive fungal infection among intensive care physicians

    ① To assess the application of pathogenetic detection and diagnostic methods of invasive fungal infections by intensive care physicians in Sichuan Province, including the technical level of fungal smear and culture, PCR detection, histopathological examination, and NGS. ②To analyse the problems and deficiencies in the diagnosis and treatment of invasive fungal infections among invasive care physicians in Sichuan Province, and to provide a reference basis for the development of targeted training and intervention measures.

    Time frame: From enrollment to the end of survey at 16 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Sep 2024, 3 months later.

Of 30 observational studies under Invasive Fungal Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Apr 4, 2024
StartEst.
Jun 1, 2024
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Apr 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06346951
Lead sponsor
Sichuan Provincial People's Hospital
Responsible party
Lingai Pan (Associate Clinical Professor, Sichuan Provincial People's Hospital) — Principal investigator
First posted
Apr 4, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Apr 4, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion